Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing
risk of breast cancer among postmenopausal and overweight or obese women who are at increased
risk of developing breast cancer. Tamoxifen is a selective estrogen receptor modulator. It
works by blocking the effects of the hormone estrogen in the breast. Tamoxifen is approved by
the Food and Drug Administration for prevention of breast cancer in women at increased risk.
Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver. Omega-3
fatty acids may work to prevent cancer in overweight or obese individuals. Tamoxifen with or
without omega-3 fatty acids may be effective at reducing risk of breast cancer among women
who are postmenopausal, overweight or obese, and at increased risk.